

# Konstantin A Senkevich

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8812098/publications.pdf>

Version: 2024-02-01

45  
papers

861  
citations

623734

14  
h-index

526287

27  
g-index

60  
all docs

60  
docs citations

60  
times ranked

1343  
citing authors

#	ARTICLE	IF	CITATIONS
1	AMPA receptor GluA2 subunit defects are a cause of neurodevelopmental disorders. <i>Nature Communications</i> , 2019, 10, 3094.	12.8	150
2	Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression. <i>Movement Disorders</i> , 2021, 36, 1420-1429.	3.9	108
3	Autophagy lysosomal pathway dysfunction in Parkinson's disease; evidence from human genetics. <i>Parkinsonism and Related Disorders</i> , 2020, 73, 60-71.	2.2	85
4	Oligomeric $\alpha$ -synuclein and glucocerebrosidase activity levels in GBA-associated Parkinson's disease. <i>Neuroscience Letters</i> , 2017, 636, 70-76.	2.1	61
5	<i>PDXK</i> mutations cause polyneuropathy responsive to pyridoxal 5-phosphate supplementation. <i>Annals of Neurology</i> , 2019, 86, 225-240.	5.3	54
6	Relevance of biomarkers across different neurodegenerative diseases. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 56.	6.2	42
7	Mutation analysis of Parkinson's disease genes in a Russian data set. <i>Neurobiology of Aging</i> , 2018, 71, 267.e7-267.e10.	3.1	40
8	Blood lysosphingolipids accumulation in patients with parkinson's disease with glucocerebrosidase 1 mutations. <i>Movement Disorders</i> , 2018, 33, 1325-1330.	3.9	34
9	New therapeutic approaches to Parkinson's disease targeting GBA, LRRK2 and Parkin. <i>Neuropharmacology</i> , 2022, 202, 108822.	4.1	33
10	Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course—a joint PhD student course at University College London and University of Gothenburg. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 20.	6.2	32
11	Fine mapping of the HLA locus in Parkinson's disease in Europeans. <i>Npj Parkinson's Disease</i> , 2021, 7, 84.	5.3	31
12	Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2021, 84, 112-121.	2.2	25
13	Plasma Cytokines Profile in Patients with Parkinson's Disease Associated with Mutations in GBA Gene. <i>Bulletin of Experimental Biology and Medicine</i> , 2020, 168, 423-426.	0.8	24
14	SNCA variants and alpha-synuclein level in CD45+ blood cells in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2018, 395, 135-140.	0.6	18
15	Plasma cytokine profile in synucleinopathies with dementia. <i>Journal of Clinical Neuroscience</i> , 2020, 78, 323-326.	1.5	16
16	Variants in the Niemann-Pick type C gene NPC1 are not associated with Parkinson's disease. <i>Neurobiology of Aging</i> , 2020, 93, 143.e1-143.e4.	3.1	13
17	LRRK2 p.M1646T is associated with glucocerebrosidase activity and with Parkinson's disease. <i>Neurobiology of Aging</i> , 2021, 103, 142.e1-142.e5.	3.1	11
18	Lack of evidence for association of UQCRC1 with Parkinson's disease in Europeans. <i>Neurobiology of Aging</i> , 2021, 101, 297.e1-297.e4.	3.1	7

#	ARTICLE	IF	CITATIONS
19	<i>SORL1</i> mutation in a Greek family with Parkinson's disease and dementia. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1961-1969.	3.7	7
20	Human Peripheral Blood Macrophages As a Model for Studying Glucocerebrosidase Dysfunction. <i>Cell and Tissue Biology</i> , 2019, 13, 100-106.	0.4	6
21	Parkinson's Disease Associated with GBA Gene Mutations: Molecular Aspects and Potential Treatment Approaches. <i>Acta Naturae</i> , 2021, 13, 70-78.	1.7	6
22	Prion Properties of Alpha-Synuclein. <i>Molecular Biology</i> , 2019, 53, 335-341.	1.3	5
23	Genetics variants and expression of the SCARB2 gene in the pathogenesis of Parkinson's disease in Russia. <i>Neuroscience Letters</i> , 2021, 741, 135509.	2.1	5
24	Increased $\alpha$ -Synuclein Level in CD45+ Blood Cells in Asymptomatic Carriers of <i>GBA</i> Mutations. <i>Movement Disorders</i> , 2021, 36, 1997-1998.	3.9	5
25	Could Blood Hexosylsphingosine Be a Marker for Parkinson's Disease Linked with <i>GBA1</i> Mutations?. <i>Movement Disorders</i> , 2022, 37, 1779-1781.	3.9	5
26	Changes of fractional anisotropy (FA) and apparent diffusion coefficient (ADC) in the model of experimental acute hydrocephalus in rabbits. <i>Acta Neurochirurgica</i> , 2015, 157, 689-698.	1.7	4
27	No Evidence for a Causal Relationship Between Cancers and Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, 11, 801-809.	2.8	3
28	Lack of Causal Effects or Genetic Correlation between Restless Legs Syndrome and Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 1967-1972.	3.9	3
29	Postural instability and neuropsychiatric disturbance in the overlapping phenotype of essential tremor and Parkinson's Disease. <i>Neurophysiologie Clinique</i> , 2020, 50, 489-494.	2.2	2
30	SNCA alleles rs356219 and rs356165 are associated with Parkinson's disease and increased $\alpha$ -synuclein gene expression in CD45+ blood cells. <i>Cell and Tissue Biology</i> , 2016, 10, 277-283.	0.4	1
31	P.114 Contribution of the SNCA gene and genes involved in autophagy in the pathogenesis of GBA-associated parkinson's disease. <i>European Neuropsychopharmacology</i> , 2021, 44, S10-S11.	0.7	1
32	$\alpha$ -Synuclein ( <i>SNCA</i> ) A30G Mutation as a Cause of a Complex Phenotype Without Parkinsonism. <i>Movement Disorders</i> , 2021, 36, 2209-2212.	3.9	1
33	P.359 Expression profile of genes involved in endolysosomal pathway in CD45+ blood cells as potential marker for differentiation of synucleinopathies. <i>European Neuropsychopharmacology</i> , 2020, 40, S208-S209.	0.7	0
34	P.101 Involvement of the genes related to lysosomal storage disorders in GBA-associated Parkinson's disease. <i>European Neuropsychopharmacology</i> , 2021, 44, S1-S2.	0.7	0
35	Glucocerebrosidase activity and transport to lysosomes in primary macrophages from patients with mutations in the GBA gene. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119511.	0.6	0
36	Alteration of expression levels of genes involved in maintaining dopaminergic system as trigger for GBA-associated Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119573.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Profiling the biochemical lysosomal activities in blood of patients with multiple system atrophy. Journal of the Neurological Sciences, 2021, 429, 117668.	0.6	0
38	Alteration of lysosomal enzymatic activities as risk factor of Parkinson's disease associated with mutations in the GBA gene. Journal of the Neurological Sciences, 2021, 429, 119577.	0.6	0
39	Genetics of Non-Motor Symptoms of Parkinson's Disease. , 2022, , 199-211.		0
41	P.0425 Link between multiple system atrophy and lysosomal storage disorders. European Neuropsychopharmacology, 2021, 53, S309.	0.7	0
42	P.0428 Alpha-synuclein alters expression levels of immediate early genes in Parkinson's disease associated with mutations in the GBA gene. European Neuropsychopharmacology, 2021, 53, S311-S312.	0.7	0
43	P.0881 Screening of CLN3 variants (rs146610181 and rs77595156) in patients with Parkinson's disease in Russia. European Neuropsychopharmacology, 2021, 53, S645-S646.	0.7	0
44	P.0730 Alteration of lysosomal activities associate with disturbance of alpha-synuclein protein level in blood of patients with GBA-associated parkinson's disease. European Neuropsychopharmacology, 2021, 53, S533.	0.7	0
45	Transcriptome analysis highlights common pathways between Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease. Alzheimer's and Dementia, 2021, 17, e050014.	0.8	0